The estimated activities of various biotechnological companies in the Asia-Pacific region have also increased up to three times as compared to the companies working in the rest of the world.
These recent changes have forced the business consulting firm Frost & Sullivan and Asia-Pacific CRO specialist Novotech to publish a report that has summarized the primary developments and trends in the Asian clinical outsourcing landscape.
The report has highlighted the key drivers behind the increasing international demand for Asia-Pacific for performing clinical research.
One of these drivers includes a large number of participants in Asia. In 2019, Asia accounted for about 60% of the global population.
A higher efficiency of complex trials due to a higher median recruitment rate and decreased recruitment periods is also another important driver, as per the report.
Lastly, the low operational costs in Asia-Pacific and the presence of knowledgeable experts and investigators have significantly contributed to the increased demand for Asia-Pacific so that the research trials could be conducted.
3 Key Points
“Novotech has differentiated itself to become the leading biotech CRO in Asia-Pacific and profoundly understands regional and complex industry needs,” said Associate Director Transformational Health Frost & Sullivan Geeta Dhanoa.
#ClinicalTrials, #ClinicalData, #Pharmaceutical, #Novotech
P.S. Want to learn more about updates in clinical trials in Asia and Asia-pacific region? Always stay informed by getting summarized articles straight to your inbox for FREE. Click here to learn more.